Trial Profile
A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2022
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PICCOLO
- 12 Jul 2021 Results assessing effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified by primary tumour location retrospectively in two studies (COIN & PICCOLO), published in the British Journal of Cancer.
- 22 Apr 2021 Results (n=274) evaluating Artificial intelligence-assisted amphiregulin and epiregulin immunohistochemistry predicts panitumumab benefit in RAS wild-type metastatic colorectal cancer published in the Clinical Cancer Research
- 17 Jan 2021 Results of retrospective biomarker study within the PICCOLO trial, evaluating AI assisted immunohistochemical tumor amphiregulin and epiregulin expression, presented at the 2021 Gastrointestinal Cancers Symposium